Evolus Inc

EOLS

Company Profile

  • Business description

    Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

  • Contact

    520 Newport Center Drive
    Suite 1200
    Newport BeachCA92660
    USA

    T: +1 949 284-4555

    E: [email protected]

    https://www.evolus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    350

Stocks News & Analysis

stocks

ASX major bank drives strong quarterly profit

Profit momentum remains robust yet shares overvalued.
stocks

Ask the analyst: What to expect in earnings season?

The key metrics that matter this earnings season.
stocks

ASX healthcare share remains undervalued ahead of earnings

Margin recovery remains the key driver for this ASX healthcare share.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,057.0029.400.33%
CAC 408,372.280.000.00%
DAX 4025,099.00335.881.36%
Dow JONES (US)51,947.25235.600.46%
FTSE 10010,736.2397.060.91%
HKSE25,230.47267.241.07%
NASDAQ24,975.82161.87-0.64%
Nikkei 22564,946.15335.000.52%
NZX 50 Index13,850.6978.400.57%
S&P 5007,411.983.680.05%
S&P/ASX 2008,887.4029.500.33%
SSE Composite Index3,834.1319.930.52%

Market Movers